AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06317571 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: fertility support education
Description: In the first module, female reproductive organs, the occurrence of pregnancy and the effect of stress on fertility are explained to women using models and training booklets. The effects of affirmation, which is one of the ways to positively affect the consciousness, and imagination, visualization and relaxation techniques, which are ways to positively affect the subconscious, on body and reproductive functions are explained. In the second module, women and their partners were also trained, and the effect of lifestyle on reproductive health was explained through the second module training booklet. In the third module, an example of a one-week program in which they could apply the methods described in the training before starting their treatments was introduced. In the fourth module, treatment process was explained to women and the practices described in the training were shared, which they could do to relax during this process.
Study NCT04246151 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vancomycin Placebo
Description: sugar pill manufactured to mimic the vancomycin 125 mg capsule
Study NCT04246151 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vancomycin Placebo
Description: sugar pill manufactured to mimic the vancomycin 125 mg capsule
Study NCT04246151 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Probiotic Placebo
Description: sugar pill manufactured to mimic 10 billion unit probiotic capsules.
Study NCT04246151 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Probiotic Placebo
Description: sugar pill manufactured to mimic 10 billion unit probiotic capsules.
Study NCT05661812 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Quationnaires and symptom registration
Description: Used to collect data about symptoms potentially characterising the allergy of MB. A shortened version of the MeDALL questionnaire (mechanisms of the development of allergic diseases) will be used to collect data about allergic diseases and symptoms. POEM questionnaire (Patient-Oriented Eczema Measure) will be used to evaluate atopic eczema once in the season of MB and once outside MB and pollen seasons. The participant will also register symptoms during two periods, preferably 6 weeks during MB season autumn (August-September) 2022 and 2 weeks outside MB and pollen seasons in January/February 2023. During the 8 weeks of symptom registration the participants will receive an e-mail every other day with questions regarding symptoms and medication.
Study NCT05661812 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: PNIF and spirometry
Description: To clarify and verify the symptoms registered by the participants we will perform measurements of Peak Nasal Inspiratory Flow (PNIF) and spirometry. PNIF and spirometry will be used to assess airway obstruction through the nose and lungs, and will be performed in and outside the seasons of MB and pollen. Spirometry will be performed pre and post inhalation of bronchodilating medicine (reversibility test). Some of the participants (patients and controls) will be randomised to nasal provocation test (NPT), performed outside the seasons of MB and pollen, and for those PNIF and spirometry will be carried out before and after NPT.
Study NCT05661812 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: SPT, spesific IgE, pBAT and NPT
Description: To evaluate the symptoms as specific for allergy the participants will be tested with skin prick test (SPT) with MB and common airway allergens, serum specific IgE (sIgE) to MB and common airway allergens, nasal provocation test (NPT) with MB and passive basophil activation test (pBAT) with MB. Blood samples for the sIgE and pBAT will be performed in MD season, while SPT and NPT will be performed outside seasons of MB and pollen. We will compare the results from SPT, sIgE and pBAT with the results from NPT to calculate sensitivity and specificity of SPT, sIgE and pBAT. All those tests demand that we are able to develop MB extracts that are suitable for those tests.
Study NCT05107895 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: online coping skills training
Description: Young people with high levels of stress were given online coping trainings. The content of this training was primarily aimed at raising awareness about stress by giving information about stress, and then information about coping methods with stress was shared and training on problem solving skills was provided.
Study NCT05107895 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: online coping skills training
Description: Young people with high levels of stress were given online coping trainings. The content of this training was primarily aimed at raising awareness about stress by giving information about stress, and then information about coping methods with stress was shared and training on problem solving skills was provided.
Study NCT04535635 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Active Release Techniques®
Description: The ART® procedure will consist of identifying and treating manipulatable lesions as per their protocols, while the sham group will receive a passable version of this technique. This information is under copyright and cannot be copied or outlined specifically in any form, including a research paper. The overarching procedure used by ART® will be explained however specific details referring to each protocol cannot be described. Muscles are shortened, and the therapist applies sufficient digital pressure to be in contact with the tissue in question. Directional tension is applied proximally along the muscle fiber direction, and then the structure is lengthened while the contact remains as described.
Study NCT04535635 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Sham Active Release Techniques®
Description: For the sham treatment, the muscle(s) in question will be taken from a lengthened to a shortened position (opposite of the protocol direction as per the ART® manual) with a broad light contact on the skin - the treating therapist will not achieve tissue depth as specified by ART® and will not attempt to take tension as is outlined in the ART® manual.
Study NCT05087771 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: injectable naltrexone
Description: 360 mg dose to be given prior to hospital discharge
Study NCT05087771 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: oral naltrexone
Description: 50 mg tab dispense 30 day supply to be given at hospital discharge
Study NCT05579977 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-07081532
Description: Oral glucagon-like peptide-1 receptor agonist
Study NCT05579977 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: No drug
Study NCT05579977 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rybelsus
Description: Oral Semaglutide
Study NCT05574023 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Use of Predictive Alarm for hypoglycaemia or hyperglycaemia
Description: Patients use CGM sensor with Predictive Alarm set at 70 mg/dl in 20 minutes for hypoglycemia and at 250 mg/dl in 20 minutes for hyperglycemia.~1. in case of alarm from the hypoglycemia predictive algorithm, the indicated treatment was 0.1g of sugar/kg of body weight;~2. in case of alarm from the hyperglycemia predictive algorithm, the indication was to give an extra shot of rapid-acting insulin. The dose will be calculated on the basis of personal insulin sensitivity factor (ISF), considering as target a blood glucose of 120 mg/dl and 250 mg/dl as the projected blood glucose level that will be reached in 20 minutes. This could be done only if there is no active insulin on-board, after at least 3 hours from the last rapid-acting insulin injection.
Study NCT05574023 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Use of Alarm on Threshold for hypoglycaemia or hyperglycaemia
Description: in case of alarm of hypoglycemia, the indicated treatment was 0.3g of sugar/kg of body weight, max 15g.~in case of alarm of hyperglycemia, the indication will be to give an extra shot of rapid-acting insulin. The dose will be calculated on the basis of personal insulin sensitivity factor (ISF), considering as target a blood glucose of 120 mg/dl and 250 mg/dl as blood glucose level to correct. This could be done only if there is no active insulin on-board, after at least 3 hours from the last rapid-acting insulin injection.
Study NCT05706922 — intervention group
Intervention type: OTHER
Intervention: Venous blood sample, vaginal swab
Description: Venous blood samples and vaginal swab will be obtained on the same day.
Study NCT03941496 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine Injection
Description: In Phase Ib dose escalation stage, 24 participants will receive AZA subcutaenously once a day for 5 days as follows:~1. 5 mg/m\^2~2. 15 mg/m\^2~3. 30 mg/m\^2~4. 50 mg/m\^2~5. 75 mg/m\^2~Results from Phase Ib are sent to FDA/IRB for approval before proceeding to Phase IIa. 36 subjects will receive AZA treatment in total (Phase Ib/IIa). Subjects in Phase II will receive a dose that induces two of the three following:~1. a decrease DNA methylation levels in genes previously identified to be persistently hyper-methylated despite successful anti-TB therapy~2. an increase in TNF and IFN-γ signaling pathways~3. an increase in ex vivo mycobacterial growth inhibition assay
Study NCT05272618 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Intravascular imaging (OCT), Invasive physiologic assessment (FFR, CFR, IMR), or Non-invasive physiologic assessment (N-13 ammonia PET)
Description: Intravascular imaging (OCT), Invasive physiologic assessment (FFR, CFR, IMR), or Non-invasive physiologic assessment (N-13 ammonia PET)
Study NCT04452565 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Drug: NA-831
Description: NA-831 is a neuroprotective drug, available at 30 mg capsule
Study NCT04452565 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: NA-831 and Atazanavir
Description: Drug: NA-831 Neuroprotective drug Other Name: Traneurocin 30 mg capsule~Drug: Atazanavir Sulfate Antiviral drug Other Name: Atazanavir Sulfate 200 mg tablet
Study NCT04452565 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: NA-831and Dexamethasone
Description: Drug: NA-831 Neuroprotective drug Other Name: Traneurocin 30 mg capsule~Drug: Dexamethasone anti-inflammatory drug Other Name: Dexamethasone 4 mg
Study NCT04452565 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Atazanavir and Dexamethasone
Description: Drug: Atazanavir Sulfate Antiviral drug Other Name: Atazanavir Sulfate 200 mg tablet Drug: Dexamethasone anti-inflammatory drug Other Name: Dexamethasone 4 mg
Study NCT04021550 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Continuous Positive Airway Pressure CPAP
Description: All subjects will be advised to use their continuous positive airway pressure (CPAP) in accordance to their physician's guidelines.
Study NCT04021550 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Continuous Positive Airway Pressure CPAP
Description: All subjects will be advised to use their continuous positive airway pressure (CPAP) in accordance to their physician's guidelines.
Study NCT04021550 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telmisartan 80mg
Description: Subjects in this group will receive 80mg/day of Telmisartan (an angiotensin receptor blocker). Treatments will be administered in pre-packaged blister packages. Subjects will take Telmisartan once per day for 6 weeks.
Study NCT06189326 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: non-penetrating deep sclerectomy
Description: Non-penetrating deep sclerectomy (NPDS) is a non-perforating filtration procedure used for the surgical treatment of medically uncontrolled open angle glaucoma. This procedure was developed in an attempt to avoid many of the postoperative complications of trabeculectomy
Study NCT06189326 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: primary combined trabeculotomy-trabeculectomy
Description: Combining trabeculotomy with trabeculectomy is one of the preferred surgical options, which showed favorable results in congenital glaucoma, and is advised mainly for treating moderate to severe forms of the disease, as the procedure provides dual pathways for aqueous drainage
Study NCT04021550 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Alpha-Lipoic Acid 600mg
Description: Subjects in this group will receive 600mg/day of Alpha-Lipoic Acid (an antioxidant). Treatments will be administered in pre-packaged blister packages. Subjects will take Alpha-Lipoic Acid once per day for 6 weeks.
Study NCT04021550 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Microcrystalline Cellulose
Description: Subjects in this group will receive two capsules of Microcrystalline Cellulose (placebo). Treatments will be administered in pre-packaged blister packages. Subjects will take placebo pills once per day for 6 weeks.
Study NCT04080180 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Contingency Management
Description: Contingency management (CM) is a behavioral method that employs external rewards for target behavior. For this study, participants will receive gift cards for adhering to Medication-Assisted Treatment (attending physician visits and adhering to buprenorphine-naloxone as determined by urine toxicology panel) during their first four visits while randomized to this condition. Participants will draw a gift card from a fishbowl each visit they are adherent. Gift cards range from $25-$100.
Study NCT04080180 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Brief Motivational Interviewing + Substance Free Activities + Mindfulness
Description: Brief Motivational Interviewing + Substance Free Activities + Mindfulness (BSM) is an intervention that uses Motivational Interviewing and Behavioral Economics strategies to increase the salience of delayed rewards by eliciting personal goals, developing opioid-free activities, and engaging in reward bundling and episodic future thinking. Participants will be offered a menu of substance free activities that has been developed in pilot work. Activities will be discussed, and participants will be asked to engage in selected activities as homework. Engagement in substance free activities will be assessed at each subsequent visit. Mindfulness components will also be included in the intervention.
Study NCT06139341 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 765845
Description: BI 765845
Study NCT06139341 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT05174455 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Niraparib Tosylate Monohydrate
Description: Given PO
Study NCT05166187 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Best Practice Advisory
Description: Patients in this arm will have a Best Practice Advisory displayed in the Electronic Medical Record (EMR) as part of the discharge order workflow.
Study NCT04974242 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physiotherapist-led exercise
Description: A programme of physiotherapist-led exercise over approximately 12 weeks.
Study NCT05527041 — intervention group
Intervention type: DEVICE
Intervention: EyeBOX Lens (EBLens)
Description: The investigational device, EBLens, consists of eye-tracking scanners and sensors, developed by AdHawk Microsystems, embedded into a rugged pair of eye-glasses. The subject will wear the EBLens form factor while seated about 40 cm from a small handheld computer screen. The subject will be instructed to watch a video on the screen, while trying not to move their head. The operator will then initiate the EBLens test sequence. During this test a video will be displayed on only a portion of the screen (aperture about 1/9 the size of the screen) for 90 seconds. The video aperture will begin in the upper left corner, and, after 10 seconds, moves in a clockwise direction around the screen for 2 cycles, each taking 40 seconds. During the scan, the following data are collected at a frame rate from 100 to 500 Hz:~* Gaze coordinates~* Pupil sizes~* Accelerometer data~* Gyroscopic data~* Rotation data~* Blink data
Study NCT04801758 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Analytical Treatment Interruption
Description: Participants will stop taking their HIV medication and will stay off HIV medication unless and until the HIV levels in their blood show that their immune system is not controlling their HIV or they meet other ART re-start criteria as noted in section Detailed Description.
Study NCT04852861 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: immunogenicity after first and second dose
Description: Humoral and cellulair immunity after first and second dose of the different vaccines administrated.
Study NCT04852861 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: immunogenicity after first and second dose
Description: Humoral and cellulair immunity after first and second dose of the different vaccines administrated.
Study NCT04721678 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Interpersonal psychotherapy
Description: Internet-based interpersonal psychotherapy aimed at reducing symptoms of depression. The content of the intervention is divided into three parts: the assessment phase (the first four weeks), the focus phase (the following five weeks), and the end phase (the last week).
Study NCT06352541 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PRO-232
Description: Moxifloxacin 0.5% and Dexamethasone Phosphate 0.1%
Study NCT06352541 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sodium Chloride 0.9%
Study NCT06413485 — intervention group
Intervention type: BEHAVIORAL
Intervention: Level of recreational water contact activities
Description: We will examine a graded classification of this exposure based on individuals' minimum level of water contact: 1) no water contact; 2) minimal contact; 3) body immersion; 4) swallowed water. Minimal contact is defined as water contact that does not result in body immersion (e.g., wading below one's waist, boating, fishing). Body immersion is defined as entering the water above one's waist (e.g., swimming, surfing, snorkelling), and swallowing water as ingestion of any amount of water.
Study NCT05800223 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Almonertinib
Description: The dosage is 110 mg/day (2 tablets/day) orally once a day
Study NCT05800223 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: SBRT
Description: SRT, 27Gy-40Gy/3-5f
Study NCT05470387 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LB1148
Description: A total of 700 mL of drug product will be administered orally as a split dose before surgery.
Study NCT05470387 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A total of 700 mL of placebo will be administered orally as a split dose before surgery.
Study NCT04684264 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Heart Failure Prevention Clinic
Description: Heart Failure Prevention Clinic is a pharmacist-directed practice in collaboration with an attending cardiologist that uses evidence-based guidelines to optimize medications and lifestyle interventions for heart failure prevention.
Study NCT05256680 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Gardening Activities
Description: In the research, the elderly in the experimental group will have gardening activities once a week for 3 months.~No intervention will be applied to the elderly in the control group during the research. They will participate in routine activities in the nursing home.
Study NCT05256680 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Gardening Activities
Description: In the research, the elderly in the experimental group will have gardening activities once a week for 3 months.~No intervention will be applied to the elderly in the control group during the research. They will participate in routine activities in the nursing home.
Study NCT05201404 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Namodenoson
Description: Adenosine A3 Receptor (A3AR) agonist
Study NCT05201404 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Control arm
Study NCT06322563 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LTC004+regorafenib
Description: LTC004,90μg/kg,IV,Day 1,Q3W; Regorafenib:Orally once daily for the first 21 days of each cycle, with 28 days as 1 cycle. Cycle 1 was dose-escalation with a starting dose of 80 mg/d, increasing by 40 mg per week until 160 mg/d, i.e., 80 mg/d in week 1 (D1\~D7), 120 mg/d in week 2 (D8\~D14), and 160 mg/d in week 3 (D15\~D21);
Study NCT05259735 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Clinical Guideline based Management
Description: Clinical guidline based management will be done for Type 2 diabetes Mellitus
Study NCT05259735 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Comparator
Description: In this arm usual management of T2DM without any clinical guideline
Study NCT06527014 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pulse Radiofrequency to the suprascapular nerve
Description: Pulse radiofrequency ablation to the Suprascapular nerve
Study NCT05824364 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: telerehabilitation
Description: Telerehabilitation activites will be tested with the aim to provide 1) continuation of rehabilitative care, focused on physical training and patients'monitoring , and 2) information in the mid-term about study goals.
Study NCT05824364 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: rehabilomic
Description: blood withdrawal (10 ml of blood, two tubes of 5 ml for serum isolation): at the hospital admission at the Cardiac Rehabilitation Unit of IRCCS Fondazione Don Gnocchi of Milan (T0) and after the rehabilitative treatment (T1)